The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -1.63 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -2.89 — no flag raisedOK
- Earnings quality 75/100 — accruals in line with cashOK
Leadership changes
From Sunshine Biopharma Inc.'s own filings, the day they're filed.
- Michel Roy · Chief Commercial Officer · appointmenteff. 2025-01-13
- Malek Chamoun · Chief Development Officer · appointment
- Marc Beaudoin · Chief Operating Officer · appointment
Latest filings
- 8-K · Company announcement2026-05-29
- 8-K · Company announcement2026-05-19
- 10-Q · Quarterly report2026-05-13
- 8-K · Company announcement2026-04-09
- 10-K · Annual report2026-04-03
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Sunshine Biopharma Inc., every answer cited🔒
- The Intelligence Brief — added when Sunshine Biopharma Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.